Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Patrick M. McDaneld"'
Autor:
Patrick M. McDaneld, Meagan Rowan, Natalie Dailey Garnes, Alison Robins, Jalen Bartek, Emma Dishner, Javier A. Adachi, Ying Jiang
Publikováno v:
Supportive Care in Cancer
Background and objectives Outpatient parenteral antimicrobial therapy (OPAT) for infections has been in use for nearly 40 years, and although it has been found safe and efficacious, its use has been studied primarily among otherwise healthy patients.
Autor:
Anne J Gonzales-Luna, Joshua M. Knight, Rachel S. Britt, Jessica T. Babic, Sarah L. Spitznogle, Selena N. Pham, Patrick M. McDaneld, Joshua A. Hendrickson
Publikováno v:
Journal of Pharmacy Practice. 34:800-813
Purpose To provide a summary of the most prominent peer-reviewed infectious diseases (ID) pharmacotherapy and Human Immunodeficiency Virus (HIV)-related articles published in 2019. Summary Houston Infectious Diseases Network (HIDN) members were asked
Publikováno v:
Antimicrob Agents Chemother
Posaconazole (POS) appears to have dose-proportional pharmacokinetics; however, there is a paucity of real-life data. We retrospectively evaluated 67 patients with hematologic cancer who had POS dose increases from 300 mg/day to either 400 mg/day (n
Autor:
Patrick M. McDaneld, Courtney Moc, Kelsey Olson, Taryn A Eubank, Anne J Gonzales-Luna, Faris S Alnezary, Noor Zaidan, Ahmed Zaki
Publikováno v:
Journal of pharmacy practice.
Purpose. To summarize the most highly esteemed, peer-reviewed, infectious diseases (ID) pharmacotherapy articles published in 2020. Summary. Members of the Houston Infectious Diseases Network (HIDN) nominated articles that were deemed to have notewor
Autor:
Ardath P Mitchell, Patrick M. McDaneld, Natalie A. Finch, Travis J Carlson, Kady Phe, Jovan Borjan, Anne J Gonzales-Luna, Farnaz Foolad
Publikováno v:
Journal of Pharmacy Practice. 32:546-557
Purpose: To summarize the top 10 most influential peer-reviewed infectious diseases (ID) pharmacotherapy articles published in the year 2018. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated articles that were thought to h
Publikováno v:
Open Forum Infectious Diseases
Background Dalbavancin (DAL) is a long-acting lipoglycopeptide, which allows for up to 2 weeks of therapy from a single dose. Outside of its FDA-approved indication for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Autor:
Terri Lynn Shigle, Micah M. Bhatti, Samuel A. Shelburne, Grace E. Benanti, Jeffrey J. Tarrand, Anne Rain T. Brown, Patrick M. McDaneld, Samuel L. Aitken
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Infections with extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli are common in patients with hematologic malignancy. The utility of cefepime and piperacillin-tazobactam as empiric therapy for ESBL-producing E. coli bacteremia in patie
Publikováno v:
Open Forum Infectious Diseases
Background OPAT helps reduce hospital length of stay, but 1 in 4 patients is readmitted within 30 days of discharge. Follow up < 30 days after discharge and laboratory monitoring during therapy have been shown to reduce hospital readmissions. However
Autor:
Grace E, Benanti, Anne Rain T, Brown, Terri Lynn, Shigle, Jeffrey J, Tarrand, Micah M, Bhatti, Patrick M, McDaneld, Samuel A, Shelburne, Samuel L, Aitken
Publikováno v:
Antimicrobial agents and chemotherapy. 63(2)
Infections with extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli are common in patients with hematologic malignancy. The utility of cefepime and piperacillin-tazobactam as empiric therapy for ESBL-producing E. coli bacteremia in patie